A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.

Published

Journal Article

BACKGROUND: Stage IV melanoma has high mortality, largely unaffected by traditional therapies. Immunotherapy including cytokine therapies and checkpoint inhibitors improves outcomes, but has significant toxicities. In this phase I/IIa trial, we investigated safety and efficacy of a dendritoma vaccine, an active, specific immunotherapy, in stage IV melanoma patients. METHODS: Autologous tumor lysate and dendritic cells were fused creating dendritoma vaccines for each patient. Phase I patients were vaccinated every 3 months with IL-2 given for 5 days after initial inoculation. Phase IIa patients were vaccinated every 6 weeks with IL-2 given on days 1, 3 and 5 after initial inoculation. Toxicity and clinical outcomes were assessed. RESULTS: Twenty-five patients were enrolled and inoculated. All dendritoma and IL-2 toxicities were

Full Text

Duke Authors

Cited Authors

  • Greene, JM; Schneble, EJ; Jackson, DO; Hale, DF; Vreeland, TJ; Flores, M; Martin, J; Herbert, GS; Hardin, MO; Yu, X; Wagner, TE; Peoples, GE

Published Date

  • April 2016

Published In

Volume / Issue

  • 65 / 4

Start / End Page

  • 383 - 392

PubMed ID

  • 26894495

Pubmed Central ID

  • 26894495

Electronic International Standard Serial Number (EISSN)

  • 1432-0851

Digital Object Identifier (DOI)

  • 10.1007/s00262-016-1809-6

Language

  • eng

Conference Location

  • Germany